Pharmacy

Your Article Summary

See Latest Articles

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a New Cholesteryl Ester Transfer Protein Inhibitor in Healthy Human Subjects
Clinical Pharmacology & Therapeutics, 07/09/09

Wolk R et al. - CP-800,569 was very well tolerated, with some nonserious gastrointestinal adverse events seen only with the 1,800-mg dose. No changes in blood pressure were observed. The possible effects of higher CP-800,569 doses on aldosterone and cortisol levels could not be excluded. The results of this study may be useful in CP-800,569 dose selection.

Today in Dosing...keeping you current

Receive free subspecialty "5-minute updates" via email

Drug-Drug Interaction Between Itraconazole and the Protease Inhibitor Lopinavir/Ritonavir
Annals of Pharmacotherapy, 11/25/09

Impact of pharmaceutical dosage form on stability and dissolution of roxithromycin
Central European Journal of Medicine, 11/24/09

Postoperative analgesia with minidose intrathecal morphine for bipolar hip prosthesis in extremely elderly patients
Journal of Anesthesia, 11/24/09

 See all of Dosing

Today in Pharmacokinetics...keeping you current

Receive free subspecialty "5-minute updates" via email

Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients
Clinical Pharmacokinetics, 11/24/09

Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas
Clinical Cancer Research, 11/20/09

Safety Profile, Pharmacokinetics, and Pharmacodynamics of Siplizumab, A Humanized Anti-CD2 Monoclonal Antibody, in Renal Allograft Recipients
Transplantation Proceedings, 11/20/09

 See all of Pharmacokinetics